Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.

Shah NP.

Clin Adv Hematol Oncol. 2011 Dec;9(12):925-6. No abstract available.

PMID:
22252660
2.

BCR-ABL1 compound mutations drive ponatinib resistance.

[No authors listed]

Cancer Discov. 2014 Nov;4(11):OF13. doi: 10.1158/2159-8290.CD-RW2014-186. Epub 2014 Sep 4.

3.

[Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].

Thomas X.

Bull Cancer. 2011 Jul;98(7):761-7. doi: 10.1684/bdc.2011.1390. Review. French.

4.

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.

Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J.

Haematologica. 2013 Nov;98(11):e141-2. doi: 10.3324/haematol.2013.092882. No abstract available.

5.

Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.

Nickel RS, Daves M, Keller F.

Pediatr Blood Cancer. 2015 Nov;62(11):2050-1. doi: 10.1002/pbc.25551. Epub 2015 May 4. No abstract available.

PMID:
25939962
6.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14.

7.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M.

N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.

8.
9.

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.

Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TC, Marais R.

Ann Oncol. 2015 Jun;26(6):1180-7. doi: 10.1093/annonc/mdv110. Epub 2015 Feb 23.

10.

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ.

Clin Cancer Res. 2011 Jan 15;17(2):212-21. doi: 10.1158/1078-0432.CCR-09-3314. Epub 2010 Nov 22.

11.

Ponatinib for chronic myeloid leukemia.

Goldman JM.

N Engl J Med. 2012 Nov 29;367(22):2148-9. doi: 10.1056/NEJMe1210796. No abstract available.

PMID:
23190226
12.

[Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].

Camañas-Troyano C, Calderón-Acedos C, Moriel-Sánchez Mdel C, Segura-Bedmar M.

Farm Hosp. 2013 Sep-Oct;37(5):428-9. doi: 10.7399/FH.2013.37.5.759. Spanish. No abstract available.

13.

Where exactly does ponatinib fit in chronic myelogenous leukemia?

Berman E.

J Natl Compr Canc Netw. 2014 Nov;12(11):1615-20.

PMID:
25361807
14.

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.

Hochhaus A, Ernst T, Eigendorff E, La Rosée P.

Ann Hematol. 2015 Apr;94 Suppl 2:S133-40. doi: 10.1007/s00277-015-2323-1. Epub 2015 Mar 27. Review.

PMID:
25814079
15.

Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.

Frankfurt O, Licht JD.

Clin Cancer Res. 2013 Nov 1;19(21):5828-34. doi: 10.1158/1078-0432.CCR-13-0258. Epub 2013 Aug 9. Review.

16.

[Management of advanced stage chronic myeloid leukemia].

Takahashi N.

Rinsho Ketsueki. 2014 Oct;55(10):1860-9. Review. Japanese. No abstract available.

PMID:
25297750
17.

Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.

Ferri CA, Bianchini M, Bengió RM, Moiraghi EB, Gonzalez MS, Noriega MF, Larripa IB.

Eur J Haematol. 2015 Mar;94(3):270-2. doi: 10.1111/ejh.12358. Epub 2014 May 13.

PMID:
24766374
18.

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X.

Chem Biol Drug Des. 2011 Jan;77(1):1-11. doi: 10.1111/j.1747-0285.2010.01054.x. Epub 2010 Nov 30.

PMID:
21118377
19.

Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shamroe CL, Comeau JM.

Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21. Review.

PMID:
24265264
20.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-42. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

Supplemental Content

Support Center